

# Clovis Oncology Denmark ApS

C/O Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 København Ø

Company reg. no. 38 72 16 82

## Annual report

1 January - 31 December 2022

The annual report was submitted and approved by the general meeting on the 14 November 2023.



---

Andreas Moin Akhtar  
Chairman of the meeting

## Contents

---

	<u>Page</u>
<b>Reports</b>	
Management's statement	3
Practitioner's compilation report	4
<b>Management's review</b>	
Company information	5
Management's review	6
<b>Financial statements 1 January - 31 December 2022</b>	
Income statement	7
Balance sheet	8
Statement of changes in equity	9
Notes	10
Accounting policies	11

Notes:

- To ensure the greatest possible applicability of this document, IAS/IFRS English terminology has been used.
- Please note that decimal points have not been used in the usual English way. This means that for instance DKK 146.940 means the amount of DKK 146,940, and that 23,5 % means 23.5 %.

## Management's statement

---

Today, the Managing Director has approved the annual report of Clovis Oncology Denmark ApS for the financial year 1 January - 31 December 2022.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

I consider the chosen accounting policy to be appropriate, and in my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January – 31 December 2022.

The Managing Director consider the conditions for audit exemption of the 2022 financial statements to be met.

Further, in my opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the Annual General Meeting.

Copenhagen, 14 November 2023

**Managing Director**



Andreas Moin Akhtar

## Practitioner's compilation report

---

### To the Management of Clovis Oncology Denmark ApS

We have compiled the financial statements of Clovis Oncology Denmark ApS for the financial year 1 January - 31 December 2022 based on the company's bookkeeping and on information you have provided.

These financial statements comprise income statement, balance sheet, statement of changes in equity, notes and a summary of significant accounting policies.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements under the Danish Act on Approved Auditors and Audit Firms and International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the Danish Financial Statements Act.

Alleroed, 14 November 2023

### Piaster Revisorerne

Statsautoriseret Revisionsaktieselskab  
Company reg. no. 25 16 00 37

Emil Lagstrøm

State Authorised Public Accountant  
mne45851

## Company information

---

### The company

Clovis Oncology Denmark ApS  
C/O Plesner Advokatpartnerselskab  
Amerika Plads 37  
2100 København Ø

Company reg. no. 38 72 16 82  
Established: 14 June 2017  
Domicile: Copenhagen  
Financial year: 1 January - 31 December

### Managing Director

Andreas Moin Akhtar

### Auditors

Piaster Revisorerne, Statsautoriseret Revisionsaktieselskab  
Engholm Parkvej 8  
3450 Allerød

## Management's review

---

### **Description of key activities of the company**

The principal activities comprise within the pharmaceutical industry, including sales, import, marketing and distribution of pharmaceutical products and services as well as other related business.

### **Development in activities and financial matters**

The company has decided to be voluntarily liquidated in 2023 or 2024, which is why all assets are measured at realisable value.

### **Events occurring after the end of the financial year**

In 2023, the company received debt forgiveness from the company's owner, so that the company is solvent.

**Income statement 1 January - 31 December**

All amounts in DKK.

<u>Note</u>	<u>2022</u>	<u>2021</u>
<b>Gross profit</b>	<b>1.268.076</b>	<b>1.539.039</b>
2 Staff costs	-1.928.250	-1.450.887
<b>Operating profit</b>	<b>-660.174</b>	<b>88.152</b>
Other financial income	0	15
3 Other financial expenses	-21.668	-32.119
<b>Pre-tax net profit or loss</b>	<b>-681.842</b>	<b>56.048</b>
4 Tax on net profit or loss for the year	-1.549	-9.712
<b>Net profit or loss for the year</b>	<b>-683.391</b>	<b>46.336</b>
<b>Proposed distribution of net profit:</b>		
Transferred to retained earnings	0	46.336
Allocated from retained earnings	-683.391	0
<b>Total allocations and transfers</b>	<b>-683.391</b>	<b>46.336</b>

**Balance sheet at 31 December**

All amounts in DKK.

<u>Note</u>	<u>2022</u>	<u>2021</u>
<b>Assets</b>		
<b>Current assets</b>		
Income tax receivables	6.000	0
Other receivables	124.108	134.542
Total receivables	<u>130.108</u>	<u>134.542</u>
Cash and cash equivalents	<u>1.509.940</u>	<u>990.633</u>
<b>Total current assets</b>	<b><u>1.640.048</u></b>	<b><u>1.125.175</u></b>
<b>Total assets</b>	<b><u>1.640.048</u></b>	<b><u>1.125.175</u></b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Contributed capital	50.000	50.000
Retained earnings	-434.329	249.062
<b>Total equity</b>	<b><u>-384.329</u></b>	<b><u>299.062</u></b>
<b>Liabilities other than provisions</b>		
Trade payables	80.202	80.454
Payables to group enterprises	1.318.373	431.344
Other payables	625.802	314.315
Total short term liabilities other than provisions	<u>2.024.377</u>	<u>826.113</u>
<b>Total liabilities other than provisions</b>	<b><u>2.024.377</u></b>	<b><u>826.113</u></b>
<b>Total equity and liabilities</b>	<b><u>1.640.048</u></b>	<b><u>1.125.175</u></b>

**1 Subsequent events**



## Statement of changes in equity

---

All amounts in DKK.

	<b>Contributed capital</b>	<b>Retained earnings</b>	<b>Total</b>
Equity 1 January 2021	50.000	202.726	252.726
Retained earnings for the year	0	46.336	46.336
Equity 1 January 2021	50.000	249.062	299.062
Retained earnings for the year	0	-683.391	-683.391
	<b>50.000</b>	<b>-434.329</b>	<b>-384.329</b>

## Notes

---

All amounts in DKK.

### 1. Subsequent events

In 2023, the company received debt forgiveness from the company's owner, so that the company is solvent.

	<u>2022</u>	<u>2021</u>
<b>2. Staff costs</b>		
Salaries and wages	1.699.426	1.254.604
Pension costs	120.758	112.612
Other staff costs	<u>108.066</u>	<u>83.671</u>
	<b><u>1.928.250</u></b>	<b><u>1.450.887</u></b>
Average number of employees	<u>1</u>	<u>1</u>
<b>3. Other financial expenses</b>		
Other financial costs	<u>21.668</u>	<u>32.119</u>
	<b><u>21.668</u></b>	<b><u>32.119</u></b>
<b>4. Tax on net profit or loss for the year</b>		
Tax on net profit or loss for the year	0	9.712
Adjustment of tax for previous years	<u>1.549</u>	<u>0</u>
	<b><u>1.549</u></b>	<b><u>9.712</u></b>

## Accounting policies

---

The annual report for Clovis Oncology Denmark ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.

As discussed in the management report, the condition for going concern has not been met. Assets and liabilities are therefore, in accordance with current accounting policies, measured at expected realizable values.

All value adjustments of assets and liabilities as well as derived operating items are consequently recognized in the income statement, including expected losses, various disposal costs, fees etc.

### Income statement

#### Gross profit

Gross profit comprises the revenue, changes in inventories of finished goods, and work in progress, own work capitalised, other operating income, and external costs.

Revenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Revenue is measured at the fair value of the consideration promised exclusive of VAT and taxes and less any discounts relating directly to sales.

#### Other external expenses

Other external expenses comprise expenses incurred for distribution, sales, advertising, administration, premises, loss on receivables, and operational leasing costs.

#### Staff costs

Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members.

#### Financial income and expenses

Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses, financial expenses from financial leasing, realised and unrealised capital gains and losses relating to securities, debt and transactions in foreign currency, amortisation of financial assets and liabilities as well as surcharges and reimbursements under the advance tax scheme, etc.

#### Tax on net profit or loss for the year

Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity.

## Accounting policies

---

### Statement of financial position

#### Receivables

Receivables are measured at amortised cost, which usually corresponds to nominal value.

Impairment losses are calculated as the difference between the carrying amount of accounts receivable and the present value of the expected cash flows, including the realisable value of any securities received. The effective interest rate for the individual account receivable or portfolio is used as the discount rate.

#### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand.

#### Income tax and deferred tax

Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.

#### Liabilities other than provisions

Financial liabilities other than provisions related to borrowings are recognised at the received proceeds less transaction costs incurred. In subsequent periods, the financial liabilities are recognised at amortised cost, corresponding to the capitalised value when using the effective interest rate. The difference between the proceeds and the nominal value is recognised in the income statement during the term of the loan.

Other liabilities concerning payables to suppliers, group enterprises, and other payables are measured at amortised cost which usually corresponds to the nominal value.

# PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

## Emil Lagstrøm

PIASTER REVISORERNE, STATSAUTORISERET REVISIONSAKTIESELSKAB

CVR: 25160037

Revisor

Serienummer: 2b1dd4cf-c1fa-485c-bd96-1eb45a048cb1

IP: 62.242.xxx.xxx

2023-11-14 10:31:06 UTC



Penneo dokumentnøgle: E7K2J-L20ZO-APE11-GGE37-5NXZZ-GXDEV

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstemplet med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

### Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service <penneo@penneo.com>**. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: **<https://penneo.com/validator>**